Tags

Type your tag names separated by a space and hit enter

The endocannabinoid system: current pharmacological research and therapeutic possibilities.
Basic Clin Pharmacol Toxicol. 2006 Feb; 98(2):124-34.BC

Abstract

In the relatively short period of time since the discovery of cannabinoid receptors and their endogenous ligands, the endocannabinoids, an intensive research effort has resulted in the identification of agents that affect all aspects of the endocannabinoid system. The cannabinoid(1) receptor antagonist rimonabant is in phase III clinical trials for the treatment of obesity and as an aid to smoking cessation, and cannabinoid(2) receptor agonists are promising in animal models of inflammatory and neuropathic pain. In the present MiniReview, the endocannabinoid system is described from a pharmacological perspective. The main topics covered are: the mechanism of action of cannabinoid(2) receptor agonists; identification of the endocannabinoid(s) involved in retrograde signalling; the elusive mechanism(s) of endocannabinoid uptake; therapeutic possibilities for fatty acid amide hydrolase inhibitors; and the cyclooxygenase-2 and lipoxygenase-derived biologically active metabolites of the endocannabinoids.

Authors+Show Affiliations

Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87 Umeå, Sweden.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16445584

Citation

Jonsson, Kent-Olov, et al. "The Endocannabinoid System: Current Pharmacological Research and Therapeutic Possibilities." Basic & Clinical Pharmacology & Toxicology, vol. 98, no. 2, 2006, pp. 124-34.
Jonsson KO, Holt S, Fowler CJ. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol. 2006;98(2):124-34.
Jonsson, K. O., Holt, S., & Fowler, C. J. (2006). The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic & Clinical Pharmacology & Toxicology, 98(2), 124-34.
Jonsson KO, Holt S, Fowler CJ. The Endocannabinoid System: Current Pharmacological Research and Therapeutic Possibilities. Basic Clin Pharmacol Toxicol. 2006;98(2):124-34. PubMed PMID: 16445584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The endocannabinoid system: current pharmacological research and therapeutic possibilities. AU - Jonsson,Kent-Olov, AU - Holt,Sandra, AU - Fowler,Christopher J, PY - 2006/2/1/pubmed PY - 2006/7/11/medline PY - 2006/2/1/entrez SP - 124 EP - 34 JF - Basic & clinical pharmacology & toxicology JO - Basic Clin. Pharmacol. Toxicol. VL - 98 IS - 2 N2 - In the relatively short period of time since the discovery of cannabinoid receptors and their endogenous ligands, the endocannabinoids, an intensive research effort has resulted in the identification of agents that affect all aspects of the endocannabinoid system. The cannabinoid(1) receptor antagonist rimonabant is in phase III clinical trials for the treatment of obesity and as an aid to smoking cessation, and cannabinoid(2) receptor agonists are promising in animal models of inflammatory and neuropathic pain. In the present MiniReview, the endocannabinoid system is described from a pharmacological perspective. The main topics covered are: the mechanism of action of cannabinoid(2) receptor agonists; identification of the endocannabinoid(s) involved in retrograde signalling; the elusive mechanism(s) of endocannabinoid uptake; therapeutic possibilities for fatty acid amide hydrolase inhibitors; and the cyclooxygenase-2 and lipoxygenase-derived biologically active metabolites of the endocannabinoids. SN - 1742-7835 UR - https://www.unboundmedicine.com/medline/citation/16445584/The_endocannabinoid_system:_current_pharmacological_research_and_therapeutic_possibilities_ L2 - https://doi.org/10.1111/j.1742-7843.2006.pto_376.x DB - PRIME DP - Unbound Medicine ER -